Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Dietz, J; Spengler, U; Müllhaupt, B; Schulze Zur Wiesch, J; Piecha, F; Mauss, S; Seegers, B; Hinrichsen, H; Antoni, C; Wietzke-Braun, P; Peiffer, KH; Berger, A; Matschenz, K; Buggisch, P; Backhus, J; Zizer, E; Boettler, T; Neumann-Haefelin, C; Semela, D; Stauber, R; Berg, T; Berg, C; Zeuzem, S; Vermehren, J; Sarrazin, C; European HCV Resistance Study Group.
Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections.
Clin Gastroenterol Hepatol. 2021; 19(1):195-198
Doi: 10.1016/j.cgh.2019.10.051
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Stauber Rudolf
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Hepatitis C virus infection is causing chronic liver disease, cirrhosis, and hepatocellular carcinoma. By combining direct-acting antivirals (DAAs), high sustained virologic response rates (SVRs) can be achieved. Resistance-associated substitutions (RASs) are commonly observed after DAA failure, and especially nonstructural protein 5A (NS5A) RASs may impact retreatment options.1-3 Data on retreatment of DAA failure patients using first-generation DAAs are limited.4-7 Recently, a second-generation protease- and NS5A-inhibitor plus sofosbuvir (voxilaprevir/velpatasvir/sofosbuvir [VOX/VEL/SOF]) was approved for retreatment after DAA failure.8 However, this and other second-generation regimens are not available in many resource-limited countries or are not reimbursed by regular insurance, and recommendations regarding the selection of retreatment regimens using first-generation DAAs are very important. This study aimed to analyze patients who were re-treated with first-generation DAAs after failure of a DAA combination therapy. Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.